ArticleJournal for immunotherapy of cancer2023

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL.

Fengmei Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.